Treatment of refractory ovarian cancer with 5-fluorouracil and leucovorin

Gynecologic Oncology

Volumn 61, Issue 2, 1996, Pages 249-252

  Préfontaine, Michel ^a   Donovan, Julia T ^a   Powell, John L ^a   Buley, Lynnette ^a  

^a BAYSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOHEXIMIDE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; IFOSFAMIDE; MELPHALAN; PACLITAXEL;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; OVARY CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STOMATITIS; TREATMENT OUTCOME;

EID: 0342398241     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0134     Document Type: Article

References (10)

1. McGuire, W. P., Rowinsky, E. K., Rosenshein, N. B., Grumbine, F., Ettinger, D., Armstrong, D., and Donehower, R. C. Taxol: A unique antineoplastic agent with significant activity in advanced epithelial ovarian neoplasms, Ann. Intern. Med. 111, 273-279 (1989).
2. Thigpen, J. T., Blessing, J. A., Ball, H., Hummel, S., and Barrett, R., Phase II trial of Taxol as second-line therapy for ovarian carcinoma: A Gynecologic Oncology Group study, Proc. Am. Soc. Clin. Oncol. 9, 156 (1990).
3. ten Bokkel, Huinink, W. W., Eisenhauer, E., and Swenerton, K. Preliminary evaluation of a multicenter, randomized comparative study of Taxol (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Canadian-European Taxol Cooperative Trial Group, Cancer Treat. Rev. 19(Suppl. C), 79-86 (1993).
4. Reed, E., Jacob, J., Ozols, R. F., Young, R. C., and Allegra, C. 5-fluorouracil (5-FU) and leucovorin in platinum refractory advanced-stage ovarian carcinoma, Gynecol. Oncol. 46, 326-329 (1992).
5. Look, K. Y., Blessing, J. A., Muss, H. B., and DeGeest, K. 5-Fluorouracil and low-dose leucovorin in the treatment of recurrent epithelial ovarian carcinoma: A phase II trial of the Gynecologic Oncology Group, Am. J. Clin. Oncol. (CCT) 15(6), 494-496 (1992).
6. Louvet, C., de Gramont, A., Demuynck, B., Varette, C., Beerblock, K., and Bennamoun, M., Bi-weekly 2-day schedule of high-dose folinic acid, 5-fluorouracil bolus and infusion in pretreated advanced epithelial ovarian cancer: A phase II study, Ann. Oncol. 3(8), 657-658 (1992).
7. Long, H. J., Nelimark, R. A., Su, J. Q., Garneau, S. C., Levitt, R., Goldberg, R. M., Poon, M. A., and Kugler, J. W., Phase II evaluation of 5-fluorouracil and low-dose leucovorin in cisplatin-refractory advanced ovarian carcinoma, Gynecol. Oncol. 54, 180-183 (1994).
8. Morgan, R. J., Speyer, J., Doroshow, J. H., Margolin, K., Raschko, J., Sorich, J., Akman, S., Leong, L., Somlo, G., Vasilev, S., Ahn, C., Johnson, D., and Beller, U. Modulation of 5-fluorouracil with high dose leucovorin calcium: Activity in ovarian cancer and correlation with CA-125 levels, Gynecol. Oncol. 58, 79-85 (1995).
9. Look, K. Y., Muss, H. B., Blessing, J. A., and Morris, M. A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma: A Gynecologic Oncology Group Study, Am. J. Clin. Oncol. 18(1), 19-22 (1995).
10. O'Connell, M. J., A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer, Cancer 63, 1026-1030 (1989).